The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In the United States, all of the northern states had abolished slavery by 1804, with New Jersey being the last to act. Abolitionist pressure produced a series of small steps towards emancipation. After the Act Prohibiting Importation of Slaves went into effect on January 1, 1808, the importation of slaves into the United States was prohibited, but not the internal slave trade, nor involvement in the international slave trade externally. Legal slavery persisted outside the northern states, but abolitionists took an active role in opposing slavery by supporting the Underground Railroad, and violent clashes between anti-slavery and pro-slavery Americans occurred, including in Bleeding Kansas, a series of political and armed disputes in 1854–1858 as to whether Kansas would join the United States as a slave or free state. By 1860, the total number of slaves reached almost four million, and the American Civil War, beginning in 1861, led to the end of slavery in the United States. Slaves in areas controlled by the Confederacy were legally emancipated in 1863, when Lincoln issued the Emancipation Proclamation, and slavery was banned nationwide, except as punishment for a crime, in 1865, with the ratification of the 13th Amendment to the U.S. Constitution. Many of the freed slaves became sharecroppers and indentured servants.
Napier) (World Scientific, Hackensack NJ, 2010) ISBN 9789812814005 A Journey with Fred Hoyle, Second Edition (World Scientific, Singapore, April 2013) ISBN 9789814436120 The search for our cosmic ancestry, World Scientific, New Jersey 2015, ISBN 978-981-461696-6. Walker, Theodore; Wickramasinghe, Chandra (2015). The Big Bang and God: An Astro-Theology. Palgrave Macmillan US. doi:10.1057/9781137535030. ISBN 978-1-349-57419-3.
== Epidemiology == Diabetic ketoacidosis occurs in 4.6–8.0 per 1000 people with diabetes annually. Rates among those with type 1 diabetes are higher with about 4% in the United Kingdom developing DKA a year while in Malaysia the condition affects about 25% a year. In the United States, 135,000 hospital admissions occur annually as a result of DKA, at an estimated cost of $2.4 billion or a quarter to half the total cost of caring for people with type 1 diabetes. There has been a documented increasing trend in hospital admissions. The risk is increased in those with an ongoing risk factor, such as an eating disorder, and those who cannot afford insulin. About 30% of children with type 1 diabetes receive their diagnosis after an episode of DKA. Lower socio‐economic status and higher area‐level deprivation are associated with an increased risk of diabetic ketoacidosis in people with diabetes mellitus type 1. Previously considered universally fatal, the risk of death with adequate and timely treatment is between <1% and 5%. However, despite low acute mortality rates, an episode of DKA remains a significant predictor of death over the subsequent 12 months. Up to 1% of children with DKA develop a complication known as cerebral edema. Rates of cerebral edema in US children with DKA have risen from 0.4% in 2002 to 0.7% in 2012. Between 2 and 5 out of 10 children who develop brain swelling will die as a result.
=== In art === Teleost fishes have been frequent subjects in art, reflecting their economic importance, for at least 14,000 years. They were commonly worked into patterns in Ancient Egypt, acquiring mythological significance in Ancient Greece and Rome, and from there into Christianity as a religious symbol; artists in China and Japan similarly use fish images symbolically. Teleosts became common in Renaissance art, with still life paintings reaching a peak of popularity in the Netherlands in the 17th century. In the 20th century, different artists such as Klee, Magritte, Matisse and Picasso used representations of teleosts to express radically different themes, from attractive to violent. The zoologist and artist Ernst Haeckel painted teleosts and other animals in his 1904 Kunstformen der Natur. Haeckel had become convinced by Goethe and Alexander von Humboldt that by making accurate depictions of unfamiliar natural forms, such as from the deep oceans, he could not only discover "the laws of their origin and evolution but also to press into the secret parts of their beauty by sketching and painting".
Sources: en.wikipedia.org
Sam Lonergan (born 26 March 1987) is a former professional Australian rules footballer who played for the Essendon Football Club and Richmond Football Club in the Australian Football League (AFL). He was drafted from the Launceston Football Club, via the Tassie Mariners U18s and the Tasmanian Devils, with selection 50 in the 2005 Draft. Lonergan captained the Allies (a composite team drawn from Tasmania, New South Wales, Queensland, the Australian Capital Territory and the Northern Territory), against Victoria during Grand Final week. In that game, he kicked five goals and was the leading possession winner on the ground. He also became the first player in the history of the Tassie Mariners U18s to win successive best and fairest awards. He also played eight games in 2005 for the Tasmanian Devils Football Club in the VFL competition. Lonergan was chosen as Tasmania's most valuable player at the under-18 championships in 2005, and won the Tassie Mariners U18 Best & Fairest award that same year. He was also chosen in the under-18 All-Australian side. After a 2012 season where he played 14 games and broke the shoulder blade of Andrew Carrazzo; he was delisted by the Essendon Football Club on 30 October 2012. Lonergan was picked up by Richmond in the 2012 Rookie draft, played two games for the club in 2013 and retired at the end of that year. Lonergan also supported Richmond while growing up.
2 CoF2 + F2 → 2 CoF3 Industrially, both steps are combined, for example in the manufacture of the Flutec range of fluorocarbons by F2 chemicals Ltd, using a vertical stirred bed reactor, with hydrocarbon introduced at the bottom, and fluorine introduced halfway up the reactor. The fluorocarbon vapor is recovered from the top.
Transfer RNAs (TRNAs) are small noncoding RNA chains (74–93 nucleotides) that transport amino acids to the ribosome. The repertoire of TRNA genes varies widely between species, with some bacteria having between 20 and 30 genes while complex eukaryotes could have thousands. TRNAs have a site for amino acid attachment, and a site called an anticodon. The anticodon is an RNA triplet complementary to the mRNA triplet that codes for their cargo amino acid. Aminoacyl TRNA synthetases (enzymes) catalyze the bonding between specific TRNAs and the amino acids that their anticodon sequences call for. The product of this reaction is an aminoacyl-TRNA. The amino acid is joined by its carboxyl group to the 3' OH of the TRNA by an ester bond. When the TRNA has an amino acid linked to it, the TRNA is termed "charged". Aminoacyl-TRNA synthetases that mispair TRNAs with the wrong amino acids can produce mischarged aminoacyl-TRNAs, which can result in inappropriate amino acids at the respective position in the protein. This "mistranslation" of the genetic code naturally occurs at low levels in most organisms, but certain cellular environments cause an increase in permissive mRNA decoding, sometimes to the benefit of the cell. The ribosome has two binding sites for TRNA. They are the aminoacyl site (abbreviated A), and the peptidyl site/ exit site (abbreviated P/E). Concerning the mRNA, the three sites are oriented 5' to 3' E-P-A, because ribosomes move toward the 3' end of mRNA. The A-site binds the incoming TRNA with the complementary codon on the mRNA.
Sources: en.wikipedia.org
Pyruvate:ferredoxin oxidoreductase, which converts pyruvate into acetyl-CoA and CO2 while reducing the ferredoxin. Hydrogenase, which converts H+ into H2 while oxidizing the ferredoxin. Acetyl-CoA synthetase (in reverse), which converts acetyl-CoA and ADP + Pi into acetate, coenzyme A, and ATP. (A variant of the reaction uses acetate:succinate CoA transferase and succinyl-CoA synthatase in reverse.) The net reaction is conversion of singular equivalents of pyruvate, ADP, and Pi into ATP, CO2, acetate, and H2.
Solvent extraction is used to extract individual lanthanoid elements from the mixtures found in nature in ores such as monazite. In one process, the metal ions in aqueous solution are made to form complexes with tributylphosphate (TBP), which are extracted into an organic solvent such as kerosene. Complete separation is effected by using a countercurrent exchange method. A number of cells are arranged as a cascade. After equilibration, the aqueous component of each cell is transferred to the previous cell and the organic component is transferred to the next cell, which initially contains only water. In this way the metal ion with the most stable complex passes down the cascade in the organic phase and the metal with the least stable complex passes up the cascade in the aqueous phase. If solubility in the organic phase is not an issue, a selectivity coefficient is equal to the ratio of the stability constants of the TBP complexes of two metal ions. For lanthanoid elements which are adjacent in the periodic table this ratio is not much greater than 1, so many cells are needed in the cascade.
Banana Skids Climpies Double Lollies Fruity Pops Fun Gums Snap & Crackle Mr Chews Rainbow Dust Rainbow Drops Love Hearts Double Dip Tango Orange Flavour Chew Bar Stinger Tutti-Fruiti Flavour Chew Bar Crystal Fruits
== Scoring == The LP-IR score ranges from 0 (most insulin-sensitive) to 100 (most insulin-resistant). It's calculated by weighting the six parameters, which are more strongly correlated with insulin resistance than individual lipid measures like triglycerides or HDL cholesterol alone. Results are typically categorized:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.